Bio & Pharma
S.Korea’s stent maker Taewoong Medical acquired by Olympus for $370 million
The move seeks to raise the buyer’s gastroenterology portfolio in such devices including those for organ obstruction and stenosis
By Feb 27, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
NPS to commit $1.1 billion to external managers in 2024
Samsung shifts to emergency mode with 6-day work week for executives
Samsung Heavy Industries succeeds autonomous vessel navigation
Korean battery maker SK On expects business turnaround in H2
Japanese medical device company Olympus on Saturday said it will wholly acquire South Korea’s Taewoong Medical, a maker of gastrointestinal (GI) stents, for $370 million (488 billion won).
Taewoong Medical is a medical device company that develops and sells stents for digestive organs such as the biliary tract, esophagus, colon and duodenum. GI stents are used to treat organ blockage and strictures caused by cancer and other diseases.
Olympus expects its acquisition to enable its introduction of a wide range of GI-related products.
“We are recognized for accumulating over 30 years of technological and product innovation and differentiation, exporting GI stents to 86 countries,” said Taewoong Medical CEO Shin Kyong-min. “We will focus in raising our capacity to provide better products to medical staff and patients.”
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Mergers & AcquisitionsHankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
May 03, 2024 (Gmt+09:00)
-
Shipping & ShipbuildingHD Hyundai, ABS to set standards for e-propulsion ships
May 03, 2024 (Gmt+09:00)
-
Hydrogen economyHyundai to expand US hydrogen truck business with California nonprofit
May 03, 2024 (Gmt+09:00)
Comment 0
LOG IN